ANI Pharmaceuticals (ANIP) Stock Analysis & Winston Score

ANI Pharmaceuticals is a specialty pharmaceutical company that makes both branded and generic prescription drugs. Its products include treatments for rare diseases, hormonal conditions, and other chronic illnesses, sold mainly to hospitals, pharmacies, and healthcare distributors across the United States. The company's branded rare disease segment, built around its Cortrophin Gel product, has become a key part of its identity in recent years. ANI makes money by selling finished drug products directly to wholesalers and distributors, earning revenue from both its higher-margin branded medicines and its larger-volume generic portfolio. The company operates primarily in the U.S. market and generates roughly $600–700 million in annual revenue, with its strong gross margin reflecting the pricing power of specialty and rare disease drugs. The main growth driver is expanding Cortrophin Gel's market penetration, but the company faces ongoing risk from generic competition eroding pricing on its non-branded products and the high cost of maintaining a rare disease commercial operation.